Douglas Sites has joined Rosetta Genomics as its executive vice president of sales and marketing, a newly created position. Before Rosetta, Sites was vice president of sales and marketing at Asuragen. Prior to that, he served as director of sales for hematology and oncology at Plus Diagnostics.


Nanosphere has appointed private equity investor Kristopher Wood to its board of directors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.